RUNX1T1 and acute myeloid leukemia: In summary, the novel LSD1 inhibitor JL1037 exhibited strongly anti-leukemia effect on AML cell lines and primary AML cells, and also significantly prolonged survival time of leukemia mouse harboring AML1-ETO translocation.